Walleye Capital LLC Acquires New Shares in INmune Bio, Inc. (NASDAQ:INMB)

Walleye Capital LLC bought a new position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 33,719 shares of the company's stock, valued at approximately $157,000. Walleye Capital LLC owned about 0.15% of INmune Bio as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of INmune Bio during the 4th quarter worth about $2,221,000. Renaissance Technologies LLC raised its stake in shares of INmune Bio by 73.3% in the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company's stock valued at $868,000 after acquiring an additional 78,600 shares during the period. State Street Corp lifted its holdings in shares of INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company's stock worth $1,220,000 after acquiring an additional 58,838 shares during the last quarter. Westside Investment Management Inc. boosted its position in shares of INmune Bio by 57.3% during the 3rd quarter. Westside Investment Management Inc. now owns 71,315 shares of the company's stock worth $384,000 after purchasing an additional 25,975 shares during the period. Finally, Barclays PLC increased its holdings in INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock valued at $157,000 after purchasing an additional 24,906 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on INMB shares. Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They set a "buy" rating and a $23.00 price target on the stock. Maxim Group raised their target price on INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Scotiabank boosted their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 11th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a "strong-buy" rating in a research note on Tuesday, January 28th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, INmune Bio presently has a consensus rating of "Buy" and a consensus price target of $22.80.

INmune Bio Price Performance

INMB opened at $7.82 on Friday. The business has a fifty day moving average price of $7.84 and a 200 day moving average price of $6.70. INmune Bio, Inc. has a 12 month low of $4.32 and a 12 month high of $12.72. The stock has a market capitalization of $179.73 million, a price-to-earnings ratio of -3.59 and a beta of 1.86.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.14. On average, research analysts anticipate that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Want to see what other hedge funds are holding INMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for INmune Bio, Inc. (NASDAQ:INMB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.